AAV9 supports wide-scale transduction of the CNS and TDP-43 disease modeling in adult rats

• Published in: Molecular therapy. Methods & clinical development Vol. 2; p. 15036
• Main Authors: Jackson, Kasey L, Dayton, Robert D, Klein, Ronald L
• Format: Journal Article
• Language: English
• Published: United States Elsevier Limited 01.01.2015; Nature Publishing Group; Elsevier
• Subjects: Adeno-associated virus
• ISSN: 2329-0501; 2329-0501
• DOI: 10.1038/mtm.2015.36

AAV9 has emerged as an efficient adeno-associated virus (AAV) serotype for gene transfer to the central nervous system. We have used this technique to study aspects of amyotrophic lateral sclerosis (ALS) by administering AAV encoding the ALS-related gene transactive response DNA binding protein of 43 kDa (TDP-43) to neonatal rats. However, inducing the expression in adult subjects would be preferable to mimic the adult onset of symptoms in ALS. We expressed either green fluorescent protein (GFP) or TDP-43 in adult rats after an intravenous (i.v.) route of administration to attempt wide-scale transduction of the spinal cord for disease modeling. In order to optimize the gene transfer, we made comparisons of efficiency by age, gender, and across several AAV serotypes (AAV1, AAV8, AAV9, and AAV10). The data indicate more efficient neuronal transduction in neonates, with little evidence of glial transduction at either age, no gender-related differences in transduction, and that AAV9 was efficient in adults relative to the other serotypes tested. Based on these data, AAV9 TDP-43 was expressed at three vector doses in adult female rats yielding highly consistent, dose-dependent motor deficits. AAV9 can be delivered i.v. to adult rats to achieve consistent pathophysiological changes and a relevant adult-onset system for disease modeling.